TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Workplace Motivation, Job-Satisfaction, and Wellness, Among Nurses and Managers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* • Registered Nurse, Manager, or Clinical Supervisor employed at the hospital.~  * Employed by Billings Clinic for a minimum of 6 months.~ * Plan to be in the community for 12-18 months.~ * Proficiency in spoken and written English.~Exclusion Criteria:~* • New employee, defined as \<6 months employment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Intervention Group (Type: EXPERIMENTAL): The proposed study will be implemented as an intervention study at two levels within the organization, managerial and registered nurses. The intervention comprises three major phases: a pre-intervention phase, an implementation-intervention phase, and a post-intervention phase. The interventions will be provided face-to-face by trained interventionists. At baseline, all participants will complete questionnaires and get labs completed, blood pressure checked, and weight/height measured.~Consists of two main parts. In the first part, both managers and employees will be trained in the principles of SDT and JD-R. For managers, particular attention will be paid to the provision of need support and work values. For employees, particular attention will be paid to employees' opportunities for job crafting and promoting their basic psychological need satisfaction at work.
- Control Group (Type: NO_INTERVENTION): Participants randomized to the control group will complete the baseline questionnaires and lab tests at baseline and three follow-up times. Lab values will be collected using the current standard of care and American Heart Association (AHA) guidelines (2019).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Caregiver Assessments of the Quality of Home Hospice Care

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Bereaved family caregivers who completed their participation in the parent protocol (2006-0494) and have lost their loved one within 3-23 months.~2. Caregivers who participated in the parent grant met the inclusion/exclusion criteria of the parent grant.~Exclusion Criteria:~1. Bereaved family caregivers who did not complete their participation in the parent protocol or any other caregiver who was never enrolled in the parent protocol (2006-0494).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Caregivers (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed follicular lymphoma~* CD20+ at time of diagnosis or subsequently~* More than 4 weeks since prior rituximab~* More than 3 weeks since prior anticancer therapy (6 weeks for nitrosourea or mitomycin C)~* More than 4 weeks since prior major surgery~* More than 2 weeks since prior investigational drugs~Exclusion Criteria:~* AIDS-related lymphoma~* History or evidence of CNS involvement~* Pregnant or nursing~* known HIV positivity~* serious medical or psychiatric illness that would preclude study participation~* myocardial infarction within the past 6 months~* congestive heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or ECG evidence of acute ischemia or active conduction system abnormalities~* known hypersensitivity to rituximab, bortezomib, boron, or mannitol~* prior autologous or allogeneic stem cell transplantation~* prior radioimmunoconjugate therapy or prior exposure to murine antibodies~* prior external-beam irradiation to \> 25% of active bone marrow

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- bortezomib, Ibritumomab tiuxetan, rituximab (Type: EXPERIMENTAL): Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase I/II Study of Neoadjuvant Chemoradiotherapy With S-1/ Oxaliplatin in Patients With Gastric Cancer: Randomized Phase II Study of S-1/RT vs. S-1/Oxaliplatin/RT

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients older than 18 years~  * Patients with localized, histologically confirmed gastric or gastroesophageal adenocarcinoma ③ Localized gastric cancer of clinical stage (T2N(+), T3/T4)~    * ECOG performance status of 0 to 1 ⑤ Adequate organ function as evidenced by the following; Absolute neutrophil count \> 1.5 x 109/L; platelets \> 100 x 109/L; total bilirubin ≤1.5 UNL; AST and/or ALT \< 5 UNL; creatinine clearance ≥ 50mL/min ⑥ Written informed consent form~Exclusion Criteria:~* T1 (regardless of N stage), T2N0~  * M1 ③ Peritoneal seeding ④ Uncontrolled medical condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- S-1/oxaliplatin/RT (Type: EXPERIMENTAL): Radiotherapy + 4 dose levels of oxaliplatin/S-1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Liposomal Bupivacaine for Acute Pain in Hip and Femur Fractures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. age ≥18 years ≤ 70 years~2. Patient's s/p trauma, with confirmed femur and/or hip fractures with a planned admission to the hospital~3. Patient is ambulatory without assistance (e.g. walker, cane, caretaker) prior to incident.~Exclusion Criteria:~1. \>10 hours since presentation to the emergency department~2. History of seizure disorder, recent seizure or a document intra-cranial hemorrhage.~3. Central or peripheral neurologic deficit on presentation~4. Concern or compartment syndrome~5. Associated additional long bone fractures~6. End stage liver failure~7. Renal failure requiring dialysis~8. Pregnancy or breast feeding~9. Prisoners~10. Coagulopathy with INR \>1.5~11. Use of direct thrombin inhibitors (bivalirudin, argatroban, desirudin, dabigatran etexilate), or direct factor Xa inhibitors (rivaroxaban, apixaban, edoxaban)~12. Suspected prolonged intubation within first 12 hours secondary to respiratory failure other than peri-procedurally~13. Adults unable to consent~14. Pediatric patients \<18 years old~15. Patients exhibiting signs of shock upon admission, HR \>120 or SBP \<100 mmHg.~16. History of allergic reaction to local anesthetics~17. Administration of any other local anesthetic in the 2 hours prior to the study enrollment.~18. Distal femur fractures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Liposomal Bupivacaine (Type: ACTIVE_COMPARATOR): In patients with femur or hip fractures, a fascia iliaca compartment block using liposomal bupivacaine will be administered
- Ropivacaine HCL (Type: PLACEBO_COMPARATOR): In patients with femur or hip fractures, a fascia iliaca block using using 0.2% ropivacaine will be administered

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Titanium Niobium Nitride Coating in Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients candidate for unilateral primary total knee arthroplasty~Exclusion Criteria:~* Existing orthopaedic metal implants~* A history of hypersensitivity to metals~* Preoperative patch-test positivity to Co, Cr, Ni and Ti~* Malignancies~* Renal insufficiency~* Severe illnesses that would impair participation in this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Patients undergoing unilateral TKA (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Vulnerable Plaque Imaging in NSTEMI

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Prolonged symptoms suspected of cardiac origin (angina pectoris or angina equivalent), and presentation on the cardiac emergency department \<24 hours after symptom onset~* Elevated levels of high-sensitivity troponin T (\>14ng/L; initial blood sample at presentation or a second sample 3 hours after presentation)~* Only patients scheduled for invasive coronary angiography~* Age 18 years - 85 years~* Mentally competent~* Informed written consent~Exclusion Criteria:~* Conservatively managed patients who are not scheduled for invasive coronary angiography~* Refractory angina or on-going severe ischemia requiring immediate invasive coronary angiography~* Patients requiring invasive coronary angiography \< 24 hours after admission~* Hemodynamic instability and cardiogenic shock (mean arterial pressure \< 60 mmHg)~* Severe heart failure (Killip Class ≥ III)~* ST elevation myocardial infarction (ST-elevation in 2 contiguous leads: ≥0.2mV in men or ≥0.15 mV in women in leads V2-V3 and/or ≥0.1 mV in other leads or new left bundle branch block)~* Chest pain highly suggestive of non-cardiac origin (as judged by the cardiac emergency department physician/cardiologist):~* (Suspicion of) acute aortic dissection, acute pulmonary embolism, acute peri-myocarditis~* Life threatening arrhythmias on the cardiac emergency department or prior to presentation (sustained ventricular tachycardia, repetitive non-sustained ventricular tachycardia, ventricular fibrillation, sino-artial or atrio-ventricular block)~* Atrial fibrillation with ventricular rate ≥100 beats per minute (bpm)~* Tachycardia (≥100/bpm)~* Angina pectoris secondary to anaemia (\<5.6 mmol/L), untreated hyperthyroidism, or severe hypertension (\>200/110 mmHg)~* More than mild aortic and mitral valve calcification or stenosis by latest echocardiography~* Pregnancy~* Breast feeding women~* Life expectancy \<2 years (malignancy, etc.)~* Refusal of data storage until 15 years after end of study~* Participation in another investigational study that has not reached its primary endpoint~* Contraindications to cardiac magnetic resonance imaging

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Motor Sparing Block vs. Peri-Articular Catheters

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Adult patients ASA physical status 1-3, Ability to give informed consent, No contraindications to regional techniques, Ability to perform study related tests, Scheduled for primary unilateral total knee arthroplasty~Exclusion Criteria:~Revision of arthroplasty, Allergy to local anesthetics and multimodal analgesic drugs, Contraindications to spinal anesthesia, Inability to perform study related procedures, Inability to give informed consent, Wheel chair bound, Pregnancy, Chronic renal failure, BMI \>45

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Motor Sparing Nerve Block (Type: ACTIVE_COMPARATOR): Motor sparing knee block (60mL of 0.5% ropivacaine with 10 mg Morphine, 30 mg Ketorolac and 150 mcg of epinephrine as the initial bolus) initiated in the preoperative period in the block room as per the standard practice and continued until discharge. Spinal anesthetic with 15 mg of hyperbaric bupivacaine. Patients will be connected to an Ambit infusion pump in the postoperative period set to deliver ropivacaine 0.2% at a basal infusion rate of 7 mL/Hr with patient controlled boluses of 5mL every hour for breakthrough pain. Patients will be discharged home following removal of the anaesthetic catheter and fulfilling criteria for discharge.
- Peri-Articular Catheters (Type: EXPERIMENTAL): 3 peri-articular catheters inserted at the end of surgery followed by peri-articular infiltration with ropivacaine 0.2% and wound infusions will be continued until discharge using elastomeric devices. Spinal anesthetic with 15 mg of hyperbaric bupivacaine. Patients will be discharged home following removal of the anaesthetic catheter and fulfilling criteria for discharge.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed diagnosis of a non-myeloid malignancy~* Baseline hemoglobin (Hb) value of \<= 11.0 g/dL unrelated to transfusion~* No Packed Red Blood Cell (PRBC) or platelet transfusions in the 28 days prior to randomization~* Scheduled to receive chemotherapy for a minimum of 12 weeks during the study~* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 - 2~Exclusion Criteria:~* No planned non-palliative radiation during the study~* No current anemia due to factors other than cancer/chemotherapy (eg, iron deficiency or gastrointestinal bleeding)~* No uncontrolled hypertension (defined as systolic pressure \> 180 and/or a diastolic pressure \> 100 mmHg while receiving antihypertension therapy)~* No history of Deep Venous Thrombosis (DVT) or Pulmonary Embolus (PE) within 12 months before study enrollment. Prior superficial thrombophlebitis is not an exclusion criterion~* No history of Cerebrovascular Accident (CVA), Transient Ischemic Attack (TIA), Acute Coronary Syndrome (ACS) including unstable angina and myocardial infarction with or without ST elevation, or other arterial thrombosis within 6 months before study enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- epoetin alfa (120,000 Units) (Type: EXPERIMENTAL): epoetin alfa (PROCRIT) 120,000 Units injected subcutaneously once every 3 weeks for up to 13 weeks
- epoetin alfa (80,000 Units) (Type: EXPERIMENTAL): epoetin alfa (PROCRIT) 80,000 Units injected subcutaneously once every 3 weeks for up to 13 weeks
- darbepoetin alfa (500 mcg) (Type: ACTIVE_COMPARATOR): darbepoetin alfa (ARANESP) 500 mcg injected subcutaneously the skin once every 3 weeks for up to 13 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Controlled Trial of Intranasal Ketamine vs. Intranasal Midazolam in Individuals With OCD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-55~* Physically healthy and not currently pregnant~* Primary diagnosis of OCD~* Sufficient severity of symptoms~* For all patients on medications, medications dose must be stable for at least 6 weeks prior to enrollment. Must discuss with Dr. current medications and doses.~* Able to provide consent~Exclusion Criteria:~* First degree relative with schizophrenia~* Psychiatric conditions that would make participation unsafe determined by study doctor~* Female patients who are either pregnant or nursing~* Planning to start EX/RP during the period of the study or those who have completed an adequate dose of EX/RP (defined as 8 or more sessions within 2 months) within 8 weeks prior to enrollment.~* Nasal obstruction or history of nasal surgery~* Currently on psychotropic medication or other medication likely to interact with the glutamate system~* Medical conditions that make participation unsafe~* Allergy or intolerance to ketamine or midazolam

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Midazolam (Type: PLACEBO_COMPARATOR): A single dose of intranasal midazolam up to 4 mg
- Ketamine (Type: EXPERIMENTAL): A single dose of intranasal ketamine up to 50 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: New Therapy of Laryngeal Papilloma In Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 10 to 21 years of age~2. laryngeal papillomas requiring surgical treatment~3. willingness to participate in the study~4. a signed informed consent form by guardian or parent~Exclusion Criteria:~1. age less than 10 year old, or older than 21 year~2. guardian or parent does not understand or can not sign the consent form~3. malignant diseases such as laryngeal cancer~4. history of being hypersensitive to cabbage or other cruciferous vegetables~5. pregnancy

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- PDL+DIM pill (Type: EXPERIMENTAL): once-time 585 nm pulsed dye laser (PDL) treatment on the lesions, immediately followed by 3-month oral taking diindolylmethane (DIM, at 1.2-1.75mg/kg/day), in 15 subjects
- PDL+placebo pill (Type: PLACEBO_COMPARATOR): once-time PDL treatment on the lesions, then followed by 3-month oral taking DIM placebo, in other 15 subjects

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Transversus Abdominis Plane Blocks for Ileostomy Takedown: A Prospective Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients having an ileostomy takedown alone, on one side of abdomen~2. Ages 18-80 inclusive~3. English speaking~4. BMI less than 40~5. Ability to understand verbal pain scale~6. American Society of Anesthesiologists (ASA) Physical Status 1-3~Exclusion Criteria:~1. Allergy to local anesthetics~2. History of recent/current local or generalized infection~3. Immunocompromised~4. Significant psychiatric disease~5. History of opioid dependence~6. Pregnancy or lactation~7. A prisoner.~8. Significant liver disease~9. Contraindication to ondansetron or dexamethasone~10. Clinically significant cardiac or pulmonary disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- TAP block group (Type: EXPERIMENTAL): Patients in this group will have a preoperative, ultrasound guided injection of 30ml of 0.375% bupivacaine into the muscle plane between the transversus abdominis muscle and internal oblique muscles.
- Placebo (Type: PLACEBO_COMPARATOR): Patients in this group will have an ultrasound guided subcutaneous injection of 30 ml of sterile preservative free saline.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues